The American Journal of Medicine
Volume 121, Issue 2 , Pages 98-104 , February 2008

Abnormalities in Glucose Metabolism in Patients with Schizophrenia Treated with Atypical Antipsychotic Medications

  • Alan N. Elias, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Alan N. Elias, MD, University of California, Irvine Medical Center, 101 The City Drive South, Orange, CA 92868.
    • ,
  • Heather Hofflich, DO

References 

  1. Auquier P, Lancon C, Rouillon F, et al. Mortality in schizophrenia. Pharmacoepidemiol Drug Saf. 2006;15:873–879
  2. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration—New York metropolitan region. Schizophr Bull. 2002;28:31–42
  3. Lambert MT, Copeland LA, Sampson N, Duffy SA. New-onset type-2 diabetes associated with atypical antipsychotic medications. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:919–923
  4. Sernyak MJ, Gulanski B, Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry. 2005;66:1463–1467
  5. Cohen D, Stolk RP, Grobbee DE, Gispen-de Wied CC. Hyperglycemia and diabetes in patients with schizophrenia or schizoaffective disorders. Diabetes Care. 2006;29:786–791
  6. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? (A critical review of 17 pharmacoepidemiologic studies). Ann Clin Psychiatry. 2006;18:183–194
  7. Ananth J, Kolli S. Atypical antipsychotic agents and increased risk of diabetes: class action or differential action?. Expert Opin Drug Saf. 2005;4:55–68
  8. Bushe C, Leonard B. Association between atypical antipsychotic agents and type 2 diabetes: review of prospective clinical data. Br J Psychiatry. 2004;47(Suppl):S87–S93
  9. Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry. 2005;20(Suppl 4):S349–S357
  10. Buse JB, Cavazzoni P, Hornbuckle K, et al. A retrospective cohort study of diabetes mellitus and antipsychotic treatment in the United States. J Clin Epidemiol. 2003;56:164–170
  11. Vestri HS, Maianu L, Moellering DR, Garvey WT. Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology. 2007;32:765–772
  12. Richards AA, Hickman IJ, Wang AY, et al. Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: a potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol. 2006;26:232–237
  13. Fell MJ, Marshall KM, Williams J, Neill JC. Effects of the atypical antipsychotic olanzapine on reproductive function and weight gain in female rats. J Psychopharmacol. 2004;18:149–155
  14. Henderson DC, Copeland PM, Borba CP, et al. Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. J Clin Psychiatry. 2006;67:789–797
  15. Albaugh VL, Henry CR, Bello NT, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring). 2006;14:36–51
  16. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry. 2005;66:504–514
  17. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337–345
  18. Bechara CI, Goldman-Levine JD. Dramatic worsening of type 2 diabetes mellitus due to olanzapine after 3 years of therapy. Pharmacotherapy. 2001;21:1444–1447
  19. Houseknecht KL, Robertson AS, Zavadoski W, et al. Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects. Neuropsychopharmacology. 2007;32:289–297
  20. Sowell MO, Mukhopadhyay N, Cavazzoni P, et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab. 2002;87:2918–2923
  21. D’Alessio DA, Sandoval DA, Seeley RJ. New ways in which GLP-1 can regulate glucose homeostasis. J Clin Invest. 2005;115:3406–3408
  22. Baptista T, Martinez M, Lacruz A, et al. Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia. Schizophr Res. 2007;89:350–352
  23. Baptista T, Lacruz A, Paez X, et al. The antipsychotic drug sulpiride does not affect body weight in male rats (Is insulin resistance involved?). Eur J Pharmacol. 2002;447:91–98
  24. Rubi B, Ljubicic S, Pournourmohammadi S, et al. Dopamine D2-like receptors are expressed in pancreatic beta cells and mediate inhibition of insulin secretion. J Biol Chem. 2005;280:36824–36832
  25. Abdul-Ghani M, DeFronzo RA. Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion. J Clin Endocrinol Metab. 2007;92:1778–1784
  26. Lin EJ, Lee NJ, Slack K, et al. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. Neuropharmacology. 2006;51:1129–1136
  27. Gong DW, Bi S, Pratley RE, Weintraub BD. Genomic structure and promoter analysis of the human obese gene. J Biol Chem. 1996;271:3971–3974
  28. Hirschberg AL. Hormonal regulation of appetite and food intake. Ann Med. 1998;30:7–20
  29. Halaas JL, Gajiwala KS, Maffei M, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science. 1995;269:543–546
  30. Campfield LA, Smith FJ, Guisez Y, et al. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science. 1995;269:546–549
  31. Butte NF, Hopkinson JM, Nicolson MA. Leptin in human reproduction: serum leptin levels in pregnant and lactating women. J Clin Endocrinol Metab. 1997;82:585–589
  32. Ponzo OJ, Reynoso R, Rimoldi G, et al. Leptin stimulates the reproductive male axis in rats during sexual maturation by acting on hypothalamic excitatory amino acids. Exp Clin Endocrinol Diabetes. 2005;113:135–138
  33. Yu WH, Kimura M, Walczewska A, et al. Role of leptin in hypothalamic-pituitary function. Proc Natl Acad Sci U S A. 1997;94:1023–1028
  34. Cunningham MJ, Clifton DK, Steiner RA. Leptin’s actions on the reproductive axis: perspectives and mechanisms. Biol Reprod. 1999;60:216–222
  35. Lebrethon MC, Vandersmissen E, Gerard A, et al. In vitro stimulation of the prepubertal rat gonadotropin-releasing hormone pulse generator by leptin and neuropeptide Y through distinct mechanisms. Endocrinology. 2000;141:1464–1469
  36. Jin L, Zhang S, Burguera BG, et al. Leptin and leptin receptor expression in rat and mouse pituitary cells. Endocrinology. 2000;141:333–339
  37. Iqbal J, Pompolo S, Considine RV, Clarke IJ. Localization of leptin receptor-like immunoreactivity in the corticotropes, somatotropes, and gonadotropes in the ovine anterior pituitary. Endocrinology. 2000;141:1515–1520
  38. Cioffi JA, Shafer AW, Zupancic TJ, et al. Novel B219/OB receptor isoforms: possible role of leptin in hematopoiesis and reproduction. Nat Med. 1996;2:585–589
  39. Karlsson C, Lindell K, Svensson E, et al. Expression of functional leptin receptors in the human ovary. J Clin Endocrinol Metab. 1997;82:4144–4148
  40. Caprio M, Isidori AM, Carta AR, et al. Expression of functional leptin receptors in rodent Leydig cells. Endocrinology. 1999;140:4939–4947
  41. Geisthovel F, Jochmann N, Widjaja A, et al. Serum pattern of circulating free leptin, bound leptin, and soluble leptin receptor in the physiological menstrual cycle. Fertil Steril. 2004;81:398–402
  42. Tennekoon KH, Wasalathanthri S, Jeevathayaparan S, Karunanayake EH. Serum leptin and lactational amenorrhea in well-nourished and undernourished lactating women. Fertil Steril. 2005;83:988–994
  43. Chiu CC, Chen KP, Liu HC, Lu ML. The early effect of olanzapine and risperidone on insulin secretion in atypical-naive schizophrenic patients. J Clin Psychopharmacol. 2006;26:504–507
  44. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598–604
  45. Atmaca M, Tezcan E, Ustundag B. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain. J Psychiatr Res. 2007;41:74–79
  46. Hosojima H, Togo T, Odawara T, et al. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia. J Psychopharmacol. 2006;20:75–79
  47. Kraus T, Haack M, Schuld A, et al. Body weight and leptin plasma levels during treatment with antipsychotic drugs. Am J Psychiatry. 1999;156:312–314
  48. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry. 2000;61:742–749
  49. Bromel T, Blum WF, Ziegler A, et al. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry. 1998;3:76–80
  50. Haupt DW, Luber A, Maeda J, et al. Plasma leptin and adiposity during antipsychotic treatment of schizophrenia. Neuropsychopharmacology. 2005;30:184–191
  51. Herran A, Garcia-Unzueta MT, Amado JA, et al. Effects of long-term treatment with antipsychotics on serum leptin levels. Br J Psychiatry. 2001;179:59–62
  52. Levin F, Edholm T, Schmidt PT, et al. Ghrelin stimulates gastric emptying and hunger in normal-weight humans. J Clin Endocrinol Metab. 2006;91:3296–3302
  53. Locatelli V, Bresciani E, Bulgarelli I, et al. Ghrelin in gastroenteric pathophysiology. J Endocrinol Invest. 2005;28:843–848
  54. Muccioli G, Tschop M, Papotti M, et al. Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol. 2002;440:235–254
  55. Gnanapavan S, Kola B, Bustin SA, et al. The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab. 2002;87:2988
  56. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–660
  57. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. J Clin Endocrinol Metab. 2001;86:1169–1174
  58. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature. 2001;409:194–198
  59. Akimoto-Takano S, Sakurai C, Kanai S, et al. Differences in the appetite-stimulating effect of orexin, neuropeptide Y and ghrelin among young, adult and old rats. Neuroendocrinology. 2005;82:256–263
  60. Ukkola O, Poykko SM, Antero Kesaniemi Y. Low plasma ghrelin concentration is an indicator of the metabolic syndrome. Ann Med. 2006;38:274–279
  61. Theander-Carrillo C, Wiedmer P, Cettour-Rose P, et al. Ghrelin action in the brain controls adipocyte metabolism. J Clin Invest. 2006;116:1983–1993
  62. Schmidt PT, Degerblad M, Lindstrom E, et al. Circulating ghrelin levels after food intake during different phases of the migrating motor complex in man. Eur J Clin Invest. 2006;36:503–508
  63. Palik E, Birkas KD, Faludi G, et al. Correlation of serum ghrelin levels with body mass index and carbohydrate metabolism in patients treated with atypical antipsychotics. Diabetes Res Clin Pract. 2005;68(Suppl 1):S60–S64
  64. Murashita M, Kusumi I, Inoue T, et al. Olanzapine increases plasma ghrelin level in patients with schizophrenia. Psychoneuroendocrinology. 2005;30:106–110
  65. Theisen FM, Gebhardt S, Bromel T, et al. A prospective study of serum ghrelin levels in patients treated with clozapine. J Neural Transm. 2005;112:1411–1416
  66. Togo T, Hasegawa K, Miura S, et al. Serum ghrelin concentrations in patients receiving olanzapine or risperidone. Psychopharmacology (Berl). 2004;172:230–232
  67. Sporn AL, Bobb AJ, Gogtay N, et al. Hormonal correlates of clozapine-induced weight gain in psychotic children: an exploratory study. J Am Acad Child Adolesc Psychiatry. 2005;44:925–933
  68. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949
  69. Schatz AR, Lee M, Condie RB, et al. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system. Toxicol Appl Pharmacol. 1997;142:278–287
  70. Wiley JL, Burston JJ, Leggett DC, et al. CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol. 2005;145:293–300
  71. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature. 2001;410:822–825
  72. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci. 2002;22:9612–9617
  73. Kagaya M, Lamb J, Robbins J, et al. Characterization of the anandamide induced depolarization of guinea-pig isolated vagus nerve. Br J Pharmacol. 2002;137:39–48
  74. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol. 2001;134:563–570
  75. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol. 2004;143:520–523
  76. Cota D, Marsicano G, Tschop M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest. 2003;112:423–431
  77. Matias I, Gonthier MP, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab. 2006;91:3171–3180
  78. Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10:1665–1669
  79. Semple DM, Ramsden F, McIntosh AM. Reduced binocular depth inversion in regular cannabis users. Pharmacol Biochem Behav. 2003;75:789–793
  80. Kovasznay B, Fleischer J, Tanenberg-Karant M, et al. Substance use disorder and the early course of illness in schizophrenia and affective psychosis. Schizophr Bull. 1997;23:195–201
  81. Ujike H, Takaki M, Nakata K, et al. CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol Psychiatry. 2002;7:515–518
  82. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Ann N Y Acad Sci. 1992;654:19–32
  83. Matsuda LA. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol. 1997;11:143–166
  84. Glass M. The role of cannabinoids in neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:743–765
  85. Leweke FM, Gerth CW, Klosterkotter J. Cannabis-associated psychosis: current status of research. CNS Drugs. 2004;18:895–910
  86. Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacology. 2004;29:2108–2114
  87. Poncelet M, Barnouin MC, Breliere JC, et al. Blockade of cannabinoid (CB1) receptors by 141716 selectively antagonizes drug-induced reinstatement of exploratory behaviour in gerbils. Psychopharmacology (Berl). 1999;144:144–150
  88. Meltzer HY, Arvanitis L, Bauer D, Rein W. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry. 2004;161:975–984
  89. Voruganti LN, Slomka P, Zabel P, et al. Cannabis induced dopamine release: an in-vivo SPECT study. Psychiatry Res. 2001;107:173–177

PII: S0002-9343(07)00935-7

doi: 10.1016/j.amjmed.2007.08.036

The American Journal of Medicine
Volume 121, Issue 2 , Pages 98-104 , February 2008

Article Tools

* Image Usage & Resolution